Physician profile
Sumithra Vattigunta
NPI 1598785966
$32,108.02
in general payments reported to CMS, 2019-2025
89 companies · $6,211 in 2025
The $6,211 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,765 · 2020: $3,658 · 2021: $2,524 · 2022: $3,169 · 2023: $4,365 · 2024: $8,416 · 2025: $6,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Long Term Medical Supply Or Device Loan: $1,729 · Honoraria: $1,500 · Travel and Lodging: $877 · Education: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,323.05 |
| Long Term Medical Supply Or Device Loan | $1,729.12 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $877.12 |
| Education | $562.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,803.92 | 2019-2025 | Kisqali, Piqray |
| Pharmacosmos Therapeutics INC. | $2,660.87 | 2024-2025 | Monoferric |
| Seagen INC. | $2,163.03 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $1,846.36 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $1,830.90 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Pfizer INC. | $1,709.75 | 2019-2025 | |
| Celgene Corporation | $1,411.66 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Daiichi Sankyo INC. | $1,276.13 | 2020-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $931.12 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $829.11 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $807.18 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genentech USA, INC. | $723.59 | 2019-2025 | Polivy, Itovebi, Venclexta |
| Astellas Pharma US INC | $691.58 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Glaxosmithkline, LLC. | $649.10 | 2019-2025 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $646.01 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $620.50 | 2019-2025 | Venclexta |
| Genzyme Corporation | $610.22 | 2019-2025 | |
| Amgen INC. | $585.38 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Bayer Healthcare Pharmaceuticals INC. | $557.99 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $504.84 | 2019-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $463.98 | 2019-2023 | Imbruvica |
| Puma Biotechnology, INC. | $446.48 | 2019-2025 | |
| Eisai INC. | $398.69 | 2019-2025 | |
| Sobi, INC | $366.87 | 2022-2025 | |
| Array Biopharma INC | $349.11 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $314.34 | 2019-2025 | Cabometyx |
| Medtronic USA, INC. | $298.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.13 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Deciphera Pharmaceuticals INC. | $253.76 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Clovis Oncology, INC. | $223.93 | 2019-2022 | |
| Stemline Therapeutics INC. | $190.14 | 2023-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $173.14 | 2021-2023 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $170.63 | 2019-2025 | Onivyde, Somatuline Depot |
| Adaptive Biotechnologies Corporation | $166.70 | 2021-2025 | Clonoseq |
| Jazz Pharmaceuticals INC. | $165.84 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.22 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $144.46 | 2022-2023 | Fotivda |
| Emd Serono, INC. | $141.35 | 2022-2025 | Bavencio, Tepmetko |
| Aurobindo Pharma USA, INC. | $135.24 | 2019-2020 | |
| Taiho Oncology, INC. | $119.20 | 2019-2023 | |
| Pharmaessentia USA Corporation | $114.57 | 2022-2025 | Besremi |
| Beigene USA, INC. | $110.14 | 2021-2024 | Brukinsa |
| Dova Pharmaceuticals | $109.82 | 2019-2021 | |
| Kite Pharma, INC. | $106.95 | 2021-2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $105.84 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Global Blood Therapeutics, INC. | $102.26 | 2020-2021 | |
| Tersera Therapeutics LLC | $101.00 | 2022-2025 | Zoladex |
| Kyowa Kirin, INC. | $98.52 | 2020-2023 | Poteligeo |
| Foundation Medicine, INC. | $97.89 | 2019-2022 | |
| Legend Biotech USA INC. | $92.40 | 2024-2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $78.42 | 2019-2025 | Pyrukynd |
| Medtronic, INC. | $75.54 | 2024 | Osteocool Rf Ablation System |
| Dendreon Pharmaceuticals LLC | $71.27 | 2019-2025 | Provenge |
| Geron Corporation | $63.62 | 2025 | Rytelo |
| Octapharma USA, INC. | $59.17 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $56.24 | 2024-2025 | Libtayo |
| Acrotech Biopharma INC. | $53.93 | 2022-2023 | Beleodaq |
| Gilead Sciences, INC. | $53.57 | 2021-2023 | Trodelvy |
| Morphosys, US INC. | $53.48 | 2021-2022 | |
| Blueprint Medicines Corporation | $50.19 | 2023-2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $49.95 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $48.69 | 2022-2023 | |
| Mirati Therapeutics, INC. | $43.08 | 2023 | Krazati |
| Genmab U.S., INC. | $41.28 | 2025 | Epkinly |
| Cti Biopharma Corp. | $37.69 | 2022-2023 | Vonjo |
| Karyopharm Therapeutics INC. | $36.50 | 2022-2023 | Xpovio |
| Sirtex Medical INC | $30.87 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $30.20 | 2025 | Empaveli |
| Acceleron Pharma, INC. | $26.72 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $26.57 | 2019-2020 | |
| Biocon Biologics INC | $24.48 | 2024 | Fulphila |
| Sanofi-Aventis U.S. LLC | $24.36 | 2019 | |
| Immunocore Limited | $21.26 | 2024 | Kimmtrak |
| Beone Medicines USA, INC. | $20.08 | 2025 | Brukinsa |
| Tesaro, INC. | $19.71 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.30 | 2024 | Vivimusta |
| Helsinn Therapeutics (U.S.), INC. | $16.88 | 2019 | |
| Shire North American Group INC | $15.90 | 2019 | |
| Heron Therapeutics, INC. | $15.70 | 2021 | |
| Recordati_rare_diseases_inc. | $14.45 | 2023 | Panhematin |
| Organogenesis INC. | $14.05 | 2020 | |
| Alnylam Pharmaceuticals INC. | $13.96 | 2023 | Givlaari |
| Fortovia Therapeutics, INC. | $12.98 | 2020 | |
| Verastem, INC. | $12.60 | 2020 | |
| Organon LLC | $7.06 | 2023 | Ontruzant |
| Veracyte, INC. | $5.36 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Monoferric $2,661Kisqali $2,432Enhertu $979Keytruda $605Lynparza $508Reblozyl $504Venclexta $471Erleada $416Carvykti $395Tukysa $385Jakafi $358Rybrevant $351Xtandi $290Braftovi $285Pluvicto $268Jaypirca $268Opdivo $257Imbruvica $253Ibrance $251Ultomiris $251Datroway $248Nubeqa $247Piqray $242Padcev $231Xofigo $229Orgovyx $227Mektovi $223Lorbrena $215Lutathera $195Sarclisa $192Jemperli $192Verzenio $191Orserdu $190Zejula $189Pomalyst $189Vonjo $188Ojjaara $186Tagrisso $163Talzenna $162Welireg $151Epkinly $143Lenvima $140Qinlock $139Clonoseq $137Tivdak $132Zepzelca $130Polivy $115Scemblix $114Adcetris $112Opdualag $110Cabometyx $108Stivarga $107Vitrakvi $107Tavalisse $106Rezlidhia $106Myrisk $99.99Elrexfio $92.44Besremi $91.77Darzalex $91.10Itovebi $89.06Akeega $86.54Bevespi Aerosphere $85.97Paxlovid $84.54Ayvakit $82.54Ninlaro $82.29Zoladex $81.82Zynyz $79.27Monjuvi $79.27Retevmo $76.49Brukinsa $76.02Osteocool Rf Ablation System $75.54Eliquis $72.04Phesgo $71.62Fotivda $69.80Elahere $68.66Pyrukynd $65.91Gavreto $64.27Rytelo $63.62Xalkori $58.97Onivyde $58.04Libtayo $56.24Inlyta $55.55Tecentriq $54.96Yescarta $51.20Provenge $50.32Fruzaqla $46.48Doptelet $45.68Krazati $43.08Cablivi $42.84Bosulif $42.83Balversa $39.52Iclusig $39.21Jevtana $38.14Romvimza $36.79Nurtec Odt $35.64Vyloy $35.42Xospata $34.19Tasigna $32.21Oxbryta $30.22Empaveli $30.20
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumithra Vattigunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.